MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. - Wikidata - awgldk - TriplyDB

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

http://www.wikidata.org/entity/Q35208073

about

Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices Neuroinflammation: Ways in Which the Immune System Affects the Brain Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ?Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG Differential diagnosis of neuromyelitis optica spectrum disorders.Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future.What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings.Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome.Predictors of outcome in a large retrospective cohort of patients with transverse myelitis.Macular changes of neuromyelitis optica through spectral-domain optical coherence tomography.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.Pattern Recognition of the Multiple Sclerosis Syndrome.Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy.Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.Clinical presentation and prognosis in MOG-antibody disease: a UK study.Acute simultaneous development of brain tumour-like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis.Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.Glial and neuronal antibodies in patients with idiopathic intracranial hypertension.

P2860

Q26748229-95007D4C-1205-40E4-9879-21FBF52EE6F8 Q28080620-F437FCFC-1ACB-4343-904D-05F0E8D7940C Q28270042-75920D1E-A87E-415B-890C-88D646BA08FF Q28270642-EE5989AF-DE72-455F-BD82-A8E665969F01 Q29036090-7773584A-BDAD-476C-A679-8F0AE95E61F8 Q30371412-43B7C702-C935-4346-95FA-79A3B937F3C8 Q33645795-DF2A5A35-8C62-493C-A021-5BB3314A94A6 Q33765716-A4DCF272-9E00-4F04-BEAD-4335BBB5E30C Q33812063-4399EACE-6D18-4EBA-BDD4-0AF7F706A0CC Q35179839-CB5FA9B4-F244-431E-A510-58ECE6E00AC1 Q36170912-A6D80D06-EC03-431D-9331-89F60EA17B16 Q36484465-D795C752-5547-4538-ACE4-7B046AD72358 Q36562604-792ABC18-A224-4947-886F-7717BE524950 Q36753462-6CE828C7-6C88-47E1-AE01-D3A1D748BFBC Q37235868-F122883D-65A4-4FDC-AC40-B98B479BAF3A Q37374434-ED827C03-3E00-4A77-AA3E-F797101835CE Q37383555-DD470D7D-05B8-4CAA-9CD7-618F0A76E8FB Q37590294-DFFF821A-6F0D-4EFE-BCBA-E7BC9C87BDB8 Q38652593-A1E0758F-8D96-4C9E-AB00-7EEA43399E0C Q40079955-B8AF56E2-6F39-47E0-AAD1-B6D4AF9CB0CF Q40124475-239A3EEF-1E11-4EFA-9D55-BB24C2EA97A5 Q40281523-FE48C872-80E3-424C-8B0D-5A1E08A1C828 Q40545113-2CCAF1F7-AF0E-44B9-93DC-670930E0CFDA Q41106804-9707D185-88C8-47EC-8F98-A3994A207142 Q41927942-1C715512-3C61-408A-A382-DAEBFD0B7F08 Q41992411-37B9FB0E-906B-4EF8-BE56-F33AB844E442 Q42056761-E4AE5FCE-0311-4A0A-8852-46C60D35380A Q42361527-3A223A8C-5A31-4AE3-B4EF-A523803825F2 Q42627948-9AE5AF1F-8FBB-4213-8558-3347732558CF Q44875571-4B17489B-69A5-4E68-9C9E-7A14C9680E9D Q47096340-6F612AE0-1E23-4A41-AB62-8D9470FB866B Q47102673-FD0D1E65-7D88-491D-9318-3DF02790C76A Q47203404-046CD339-59EF-4B63-81B6-63FDD422A74C Q47581499-91740230-5BCB-4913-9C58-53A295029DD4 Q47747431-AD018D06-A33E-4DC3-AEB4-727547FF598A Q47898192-2793E082-324F-4F4B-8DB1-9070FD6BA7C7 Q47970245-976A7E48-9843-4E90-BA01-4CB6CDBFEDF3 Q48159520-0DB195F1-E10A-4C3A-ABE6-88CDCF93CDBD Q48235947-EC271BB0-CD08-4D73-8E4B-3344D650FF50 Q48363473-CD5F4D5D-3580-49C5-AE38-46C8D0D84515

P2860

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

http://www.wikidata.org/entity/Q35208073

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@ast

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@en

type

label

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@ast

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@en

prefLabel

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@ast

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

@en

P1433

Q35208073-F177DB7A-D8EA-422A-AF6D-66CE7841B972

P1476

Q35208073-6371F043-FC22-45EB-A0E6-17E5AD7F1CCA

P2093

Q35208073-0D9EFF71-2A27-4A67-85D9-58F1423B32F3

Q35208073-2D1D1D78-642C-4B51-A72D-C825067B973D

Q35208073-36850307-4B8D-497E-8F54-FE00FD8E0483

Q35208073-553287C4-9174-4980-A41E-055245D3E561

Q35208073-97C3093F-1FF2-4AD7-85E6-DD8A3F4250F5

Q35208073-986B64D4-F216-4237-8604-275BDBD21CBB

Q35208073-AE278C44-C689-41F2-BD18-5D18817D3774

Q35208073-B5DB7185-BA09-411F-BD2E-0C6F7CDAC777

Q35208073-D83EB53A-5686-40BA-BF9A-CB4A23BF2E35

Q35208073-E12D0E96-46DE-4DAB-93A5-97A3D6607B83

P2860

Q35208073-05AD79D6-56EE-4231-B5A7-CFFB7B41A83F

Q35208073-0FD76AA9-24A8-44EC-AB53-EEFB528313A2

Q35208073-1069F1D6-2E3F-4FB9-BDF2-83D5954B0F68

Q35208073-3991B4B5-2D0F-44F1-B3C6-E2013DDBBE38

Q35208073-4B1A04E1-92AA-4361-B463-C261B9BB67E3

Q35208073-81477771-A469-48C4-B328-8A8349C5BFD8

Q35208073-89389685-C065-4FFF-A6A6-A7192AAA621B

Q35208073-8DD9161B-2D0B-49FC-8687-9FFF4F7C74E9

Q35208073-8E0190A1-02F5-4011-85EA-ADD6AF82FF13

Q35208073-8E55C9C9-DF0A-40C6-8E8B-27B6F8BDCA41

P304

Q35208073-7749CA84-39D0-41AB-B0F5-39C609AA26B4

P31

Q35208073-F1575AFA-347E-4C3A-A5E6-2BF7DC64AF70

P356

Q35208073-45CAF6EF-7964-471C-85DB-5D538093F1BE

P433

Q35208073-03FDE60F-85FB-4940-AC06-6C9DCFB68631

P478

Q35208073-B5703689-2452-4169-A38A-CB4DE4631A40

P50

Q35208073-7010DB7E-92AB-43D6-8050-7FBADD8FB501

Q35208073-B1157A20-F4D8-4D0A-8DEC-8FB12C0B769F

Q35208073-E4BDDA01-8123-4BCD-9003-6821B9A4871C

P577

Q35208073-E270CEC6-0C52-4FD1-927C-F15A84494588

P5875

Q35208073-11398EAD-18A5-47AE-8D0B-DB05140BF9B3

P698

Q35208073-FF4475EE-6040-4AAE-8184-FF6D2C067C86

P921

Q35208073-C8812B0C-410B-441B-943E-9BF524721087

P932

Q35208073-2C735DFB-05F9-4005-A1D6-78A28BA23208

P356

NXI.0000000000000089

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

@en

P2093

Angela Vincent

http://www.w3.org/2001/XMLSchema#string

Bethan Lang

http://www.w3.org/2001/XMLSchema#string

George Tackley

http://www.w3.org/2001/XMLSchema#string

Ichiro Nakashima

http://www.w3.org/2001/XMLSchema#string

Jacqueline Palace

http://www.w3.org/2001/XMLSchema#string

Joao Rocha

http://www.w3.org/2001/XMLSchema#string

Kazuo Fujihara

http://www.w3.org/2001/XMLSchema#string

Kevin C O'Connor

http://www.w3.org/2001/XMLSchema#string

M Isabel Leite

http://www.w3.org/2001/XMLSchema#string

Maciej Juryńczyk

http://www.w3.org/2001/XMLSchema#string

P2860

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

Relationship between NMO-antibody and anti-MOG antibody in optic neuritis

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

The spectrum of MOG autoantibody-associated demyelinating diseases

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination

CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG

Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology

Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

P304

e89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000089

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274262372

http://www.w3.org/2001/XMLSchema#string

P698

25821844

http://www.w3.org/2001/XMLSchema#string

P921

P932

4370386

http://www.w3.org/2001/XMLSchema#string